Meeting notes from the 3rd IAS Conference. New drugs.
CCR5 antagonists created quite a buzz at IAS: several are entering phase III trials and could be available in the next 2 to 3 years.
Feinberg
Judith
J
D001938:Brazil; D065100:CCR5 Receptor Antagonists; D003226:Congresses as Topic; D003570:Cytidine Triphosphate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069454:Darunavir; D015658:HIV Infections / Q000188:drug therapy; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D016047:Zalcitabine / Q000031:analogs & derivatives
D065100:CCR5 Receptor Antagonists; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D003570:Cytidine Triphosphate; D016047:Zalcitabine; C099405:dexelvucitabine; D000069454:Darunavir